Prognostic Significance of DNA Aneuploidy and p21ras Oncoprotein Expression in Colorectal Cancer and Their Role in the Determination of Treatment Modalities
Free accessResearch articleFirst published online 2001
Prognostic Significance of DNA Aneuploidy and p21ras Oncoprotein Expression in Colorectal Cancer and Their Role in the Determination of Treatment Modalities
The purpose of the present study was to investigate the prognostic significance of DNA ploidy, S-phase fraction and p21ras oncoprotein expression in patients with colorectal cancer and to correlate these factors with the clinical behavior of the tumors and their response to therapy. Of 79 patients with colorectal cancer 57% (45/79) had early stage disease. Forty-one percent (32/79) had aneuploid tumors while 30% (24/79) of the tumors had a high (>10%) S-phase fraction. p21ras oncoprotein expression was detected in 38% (30/79) of tumors. Patients with aneuploid tumors had a worse prognosis than patients with diploid tumors (p=0.0002). Similarly, patients with high S-phase fraction tumors had a shorter survival than those with low S-phase fraction tumors (p=0.005). No such difference was found between p21ras-positive and p21ras-negative tumor subgroups. In early stage colorectal cancer, aneuploidy was closely correlated with disease outcome (p=0.029). Early stage patients with diploid tumors who received radiotherapy and chemotherapy had a better prognosis than patients with aneuploid tumors. In conclusion, DNA ploidy is a significant and independent prognostic factor in colorectal cancer. Aneuploidy and genetic alteration of the p21ras oncoprotein are important in determining the biological aggressiveness of colorectal cancer. Furthermore, DNA ploidy may identify those subgroups of patients with early stage disease who may benefit from more aggressive treatment.
WiggersT., ArendsJ.W., SchutteB.A multivariate analysis of prognostic pathologic indicators in large bowel cancer.Cancer1988; 61: 386–95.
2.
MoertalC.G., FlemingT.R., MacdonaldD.G.Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.N Engl J Med1990; 322: 352–8.
3.
QuirkeP., DixonM.F., ClydenA.D.Prognostic significance of DNA aneuploidy and cell proliferation in rectal adenocarcinomas.J Pathol1987; 151: 285–91.
4.
ChapmanM.A.S., HardcastleJ.C., ArmitageN.C.M.Five year prospective study of DNA tumor ploidy and colorectal cancer survival.Cancer1995; 76: 383–7.
5.
LanzaG., GafaR., SantiniI.Prognostic significance of DNA ploidy in patients with stage II and III colon carcinoma.Cancer1998; 82: 49–59.
6.
DelattreO., OlschwangS., LawD.J.Multiple genetic alterations in distal and proximal colorectal cancer.Lancet1989; ii: 353–6.
7.
MelingG.I., LotheR.A., BorresenA.L.The TP53 tumor suppressor gene in colorectal carcinomas. II. Relation to DNA ploidy pattern and clinicopathological variables.Br J Cancer1993; 67: 93–8.
8.
RognumT., ThorudE., LundE.Survival of large bowel carcinoma patients with different DNA ploidy.Br J Cancer1987; 56: 633–6.
9.
FisherE.R., SideritesR.H., SassR.Value of assessment of ploidy in rectal cancer.Arch Pathol Lab Med1989; 113: 525–8.
10.
TangR., HoY-S, HsuH.C.Prognostic evaluation of DNA flow cytometric and histopathologic parameters of colorectal cancer.Cancer1995; 76: 1724–30.
11.
GoyetteM.C., ChoK., FaschingC.L.Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer.Mol Cell Biol1992; 12: 1387–95.
12.
BishopJ.M.Cellular oncogene and retroviruses.Ann Rev Biochem1983; 52: 301–54.
13.
ShihT.Y., WeeksM.O., YoungH.A., ScholnickE.M.Identification of a sarcoma virus-coded phosphoprotein in non-producer cells transferred by Kirsten or Harvey murine sarcoma virus.Virology1979; 96: 64–79.
14.
GibbsJ.B., SigalI.S., PoeM., ScholnickE.M.Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules.Proc Natl Acad Sci (USA)1984; 81: 5704–8.
15.
McGrathJ.P., CaponD.J., GoeddelD.V., LevinsonA.D.Comparative biochemical properties of normal and activated human ras p21 protein.Nature1984; 310: 644–9.
16.
SweetR.W., YokoyanaS., KantaT.The product of ras in GTPase and the T24 oncogene mutant is deficient in this activity.Nature1984; 311: 273–5.
17.
WilinghamM.C., PastanI., ShinT.Y.Localisation of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscope immunocytochemistry.Cell1980; 19: 1005–14.
18.
KarnataT., FermiscoJ.R.Epidermal growth factor stimulates guanine nucleotide binding activity and phosphorylation of ras oncogene protein.Nature1984; 310: 147–50.
19.
BosJ.L.Ras oncogenes in human cancer: a review.Cancer Res1989; 49: 4682–9.
20.
BosJ.L.p21 ras: an oncoprotein functioning in growth factor-induced signal transduction.Eur J Cancer1995; 31A: 1051–4.
AaltonenL.A., PeltomakiP., LeachF.S.Clues to the pathogenesis of familial colorectal cancer.Science (Washington DC)1993; 260: 812–6.
23.
AhnenD.J., FeiglP., QuanG.Ki-ras mutation and p53 overexpression predict the clinical behaviour of colorectal cancer: A Southwest Oncology Group study.Cancer1998; 58: 1149–58.
24.
DukesC.E., BusseyH.J.The spread of rectal cancer and its effect on prognosis.Br J Cancer1958; 12: 309–20.
25.
MorsonB.C., SobinL.H.International histological classification of tumours, Vol 15. Geneva: World Health Organization, 1976.
26.
HedleyD., FridlanderM., TaylorI.Method for analysis of cellular DNA content material using flow cytometry.J Histochem Cytochem1983; 31: 1333–5.
KaplanE.L., MeierP.Non parametric estimation from incomplete observations.J Am Stat Assoc1958; 53: 457–81.
29.
DukesC.E.The classification of cancer of the rectum.J Pathol Bacteriol1932; 35: 323–32.
30.
ChapuisP.H., DentO.F., FisherR.A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer.Br J Surg1985; 72: 698–702.
31.
JassJ.R., AtkinW.S., CuzickJ.The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases.Histopathology1986; 10: 437–59.
32.
NewlandR.C., ChapuisP.H., PheilsM.T.The relationship of survival to staging and grading of colorectal carcinoma: a prospective study of 503 cases.Cancer1981; 47: 1429–39.
33.
PhilipsR.K., HittingverR., BlesovskyL.Large bowel cancer: surgical pathology and its relationship to survival.Br J Surg1984; 71: 604–10.
34.
JassJ.R., LoveS.B., NorthoverJ.M.A new prognostic classification of rectal cancer.Lancet1987; 6: 1303–6.
35.
WitzigT.E., LoprinziC.L., GonchoroffN.J.DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma.Cancer1991; 68: 879–88.
36.
KouriM., PyhonensS., MecklinJ-P. The prognostic value of DNA ploidy in colorectal carcinoma: a prospective study.Br J Cancer1990; 62: 976–81.
37.
RognumT.O., LundE., MelingG.I.Near diploid large bowel carcinomas have better five year survival than aneuploid ones.Cancer1991; 68: 1077–81.
38.
SilvestriniR., D'AgnanoI., FarandaA.Flow cytometric analysis of ploidy in colorectal cancer: a multicentric experience.Br J Cancer1993; 67: 1042–6.
39.
TubinaM., CourdiA.Cell proliferation kinetics in human solid tumors, relation to probability of metastatic dissemination and long term survival.Radiother Oncol1989; 15: 1–18.
40.
SilvestriniR., DiadoneM., CostaA.Cell kinetics of solid tumors with time and its clinical implication.Tumori1989; 75: 367–72.
41.
PintoA.E., ChavesP., FidalgoP.Flow cytometric DNA ploidy and S-phase fraction correlate with histopathologic indicators of tumor behaviour in colorectal carcinoma.Dis Colon Rectum1997; 40: 411–9.
42.
BhatavdekarJ.M., PatelD.D., ChikhlikarP.P.Overexpression of CD44: A useful independent predictor of prognosis in patients with colorectal carcinomas.Ann Surg Oncol1998; 5: 495–501.
43.
OfferhauseG.J.A., De FeyterE.P., ComelisseC.S.The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma.Gastroentrology1992; 102: 1612–9.
44.
KernS.E., FearonE.R., TersmetteK.W.Clinical and pathological associations with allelic loss in colorectal carcinoma.JAMA1989; 261: 3099–103.
45.
HamelinR., LaurentP., OlschwayS.Association of p53 mutation with short survival in colorectal cancer.Gastroenterology1994; 106: 42–8.
46.
ZenniG.C., AbahamK., HarfordF.J.Characteristics of rectal carcinomas that predict the presence of lymph node metastases: Implications of patient selection for local therapy.J Surg Oncol1998; 67: 99–103.
47.
CangK.J., EnkerW.F., MelemedM.Influence of tumor cell DNA ploidy on the natural history of rectal cancer.Am J Surg1987; 153: 184–8.
48.
MoertalC.G., FlemingT.R., MacDonaldD.G.Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes B2 colon cancer.J Clin Oncol1995; 13: 2936–43.
49.
ShulmanK., SchilskyR.Adjuvant therapy of colon cancer.Semin Oncol1995; 22: 600–10.
